Medindia

X

PAREXEL Introduces New Brand Identity Reinforcing Transformation Initiatives to Deliver Precise Fit of Expertise

Tuesday, June 1, 2010 General News J E 4
Advertisement


BOSTON, June 1 PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us,"(TM) which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients. PAREXEL's brand identity reinforces its commitment to precisely complement client organizations with strategic insight, deep scientific knowledge, tactical expertise, and a wealth of experience throughout the end-to-end product development process.

To inform its new brand identity and gather continuous input to best meet client needs, PAREXEL conducted interviews with 145 decision makers from top pharmaceutical companies and small to medium-sized biopharmaceutical companies engaged in hiring service providers for a broad range of clinical research services, regulatory affairs and medical communications, among other key product and service areas. Interviewees from the Americas, Europe and Asia were included to ensure a global perspective was incorporated into the survey process.

"Biopharmaceutical companies continue to face increasingly complex decision making amidst more stringent regulatory structures, evolving science, and growing competitive challenges. PAREXEL continues to transform our business to provide an even more precise fit with our expertise. We are focused on providing tailored solutions that match a client's specific needs by applying the right blend of resources and capabilities," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.

According to Mr. von Rickenbach, "As the nature of the relationship and underlying business model amongst sponsors and service providers has evolved over the last decade, PAREXEL has been at the forefront of collaborating with clients to develop new operating models. In this regard, PAREXEL continues to be a premier, trusted partner to our clients, who rely on us for our deep expertise and flexibility as well as the efficiencies of a worldwide infrastructure to help them more quickly achieve their goals. We provide the right guidance and high level of quality needed to accelerate our clients' product development and commercialization programs, and bring safe and effective treatments to patients sooner."

In conjunction with the introduction of its new brand identity, PAREXEL has re-launched its website at www.PAREXEL.com to better assist biopharmaceutical companies online with finding the right experts in the right geographical locations worldwide for any aspect or phase of designing and executing regional and global clinical development programs.

With 28 years of experience, more than 9,500 professionals worldwide, a robust technology infrastructure, and among one of the largest global footprints of biopharmaceutical service providers, including 71 locations in 54 countries, PAREXEL continues to be a proven and committed partner to pharmaceutical, biotechnology and medical device companies looking to bring innovative products to market. PAREXEL has helped drive the success of thousands of its clients' development programs by offering worldwide regulatory expertise, Phase I-IV clinical research services, eClinical technologies that accelerate development, and medical communications services as well as reimbursement and market access services. During the past year, PAREXEL has been recognized as a Best 10 Outsourcing Company to the Pharmaceutical Industry as part of the Global Outsourcing 100® and as Best Performing CRO by BioSingapore.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contacts: Jennifer Baird, Senior Director of Public Relations Gene Carozza/Kim Baker PAREXEL International PAN Communications Tel: +781-434-4409 Tel: +978-474-1900 Email: Jennifer.Baird@PAREXEL.com Email: PAREXEL@pancomm.com

SOURCE PAREXEL International Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
OrthoDynamix Releases New Product
S
Elsevier Foundation Invites 2010 Proposals for Inn...